This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
EYLEA General
nAMD
DMO

WELCOME TO CONFIDENCE, EXTENDED

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.1–5

 

DMO

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).1

 

With EYLEA 8 mg you could optimise your patient’s treatment journey and your clinic’s capacity1–3

Save sight

whilst minimising treatment burden2,3

Extend treatment intervals

across your clinic as far as Q202,3*†

Suppress VEGF

with a safety profile comparable to EYLEA 2 mg1–3

With only 3 loading doses and as few as 8 injections over 2 years
1‡§

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.1
†Extend treatment intervals across your DMO clinic, as far as Q20, for your eligible DMO patients.2,3
‡Patients could receive as few as 8 injections per dosing schedule within the trial protocol.2
§Loading doses refers to the initial monthly dosing phase.2

PHOTON

Optimise vision whilst minimising burden

Primary endpoint: mean change in BCVA from baseline to Week 48

With EYLEA 8 mg, patients achieved lasting BCVA gains from baseline with as few as 5 injections in Year 12*

  • EYLEA 8 mg was non-inferior vs. EYLEA 2 mg2

*Includes 3 initial monthly doses.1

  • Extend treatment intervals for eligible patients across your DMO clinic

    In PHOTON, ~9 out of 10 patients maintained 16-week treatment intervals from baseline through Week 482*

    PHOTON treatment intervals week 48

    *Patients completing Week 48: 2Q8 n=157; 8Q12 n=300; 8Q16 n=156.2

  • Extend treatment intervals for eligible patients across your DMO clinic

    In PHOTON, ~9 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 963*

    PHOTON treatment intervals week 96 updated

    *Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.3

     

    Extend treatment intervals beyond expectations

    The first and only anti-VEGF for DMO that allows for extension to treatment intervals of Q20 after reaching Q161*

    PHOTON treatment intervals week 96-2 updated

    *Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology1
    †Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.3

Discover more about how you can meet the needs of your eligible nAMD patients with EYLEA 8 mg
Dosing

Discover proactive dosing in nAMD and DMO

MoA

Discover more about the MoA of EYLEA 8 mg

DMO Safety Profile

Explore the safety profile of EYLEA 8 mg in DMO

Abbreviations

2Q8, 2 mg every 8 weeks. 8Q12, 8 mg every 12 weeks. 8Q16, 8 mg every 16 weeks. BCVA, best-corrected visual acuity. BMI, body mass index. CI, confidence interval. CRT, central retinal thickness. DMO, diabetic macular oedema. DRM, dosing regimen modification. DRSS, diabetic retinopathy severity study. ETDRS, Early Treatment of Diabetic Retinopathy Study. FAS, full analysis set. ICE, intercurrent event. LS, least squares. MMRM, mixed model for repeated measurements. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. Q24, every 24 weeks. SAF, safety analysis set. SD, standard deviation. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.

References

  1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
  2. Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
  3. Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
  4. Brown DM. Intravitreal aflibercept injection 8 mg for DME: 48-week results from the Phase 2/3 PHOTON trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
  5. ClinicalTrials.gov. NCT04429503. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04429503. Accessed: August 2024.

PP-EYL-GB-2329 | August 2024

Next Page
Safety Profile